Table 1.
Demographics and risk factors between those anticoagulated early and late
| Variable | All (n=1355) | Anticoagulated early (n=358) | Anticoagulated late or not at all (n=997) |
| Age, mean (SD) | 76 (10) | 75 (11) | 76 (10) |
| Sex, female, n (%) | 580 (43) | 147 (41) | 433 (43) |
| Hypertension, n (%) | 846 (63) | 211 (59) | 635 (65) |
| Diabetes mellitus, n (%) | 222 (16) | 54 (15) | 168 (17) |
| Hyperlipidaemia, n (%) | 597 (45) | 156 (44) | 441 (45) |
| NIHSS, median (IQR)* | 4 (2–10) | 2 (1–4) | 6 (3–11) |
| Previous stroke/TIA, n (%) | 277 (21) | 77 (22) | 200 (20) |
| Previous ICH, n (%) | 13 (1.0) | 1 (0.28) | 12 (1.22) |
| Antiplatelet therapy prior to qualifying stroke, n (%) | 703 (52) | 198 (55) | 505 (51) |
| Known cognitive impairment or dementia, n (%) | 32 (3) | 9 (3) | 23 (3) |
| Premorbid mRS, median (IQR) | 1 (1–3) | 1 (0–2) | 2 (1–3) |
| Dependent living prior to stroke, n (%) | 144 (12) | 12 (4) | 132 (16) |
| Thrombolysis, n (%) | 263 (19) | 43 (12) | 220 (22) |
| Bridging heparin, n (%) | 324 (24) | 93 (26) | 231 (23) |
| CHA2DS2-VASc score, median (IQR) | 5 (4–6) | 5 (4–6) | 5 (4–6) |
| Qualifying ischaemic stroke >1/3 territory, n (%) | 242 (18) | 22 (6) | 220 (22) |
| Qualifying ischaemic stroke lacunar, n (%) | 98 (8) | 28 (8) | 70 (8) |
| PH1 Haemorrhagic transformation, n (%) | 17 (1.3) | 0 (0%) | 17 (1.8) |
| DOAC on discharge, n (%) | 475 (37) | 164 (46) | 311 (34) |
| Statin on discharge, n (%) | 1043 (79) | 266 (75) | 777 (81) |
| Antiplatelet on discharge | 717 (53) | 114 (32) | 603 (60) |
| Cerebral microbleed presence, n (%) | 269 (21) | 74 (21) | 195 (21) |
| Moderate to severe WMH, n (%) | 368 (29) | 93 (26) | 275 (30) |
*Available in 851 of 1080 (79%) of patients with non-minor ischaemic stroke.
DOAC, direct oral anticoagulant; ICH, intracranial haemorrhage; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Score; PH1, parenchymal haemorrhage type 1; TIA, transient ischaemic attack; WMH, white matter hyperintensity.